Insights & White Papers

Analysis and research from the Exploristics team.

Insights

Statistical Insights: Smarter Clinical Trial Design using Study Simulation Can Address Recruitment Challenges

With recruitment often a key barrier to study success, discover how smarter trial design using study simulation can help to relieve this

Statistical Insights: Drug Repurposing and Real-World Data: Lessons from COVID-19

How the pandemic has heightened interest in unlocking the value of RWD.

Statistical Insights: Designing clinical studies for success and not failure

Why aren’t biostatisticians involved earlier in the clinical trial design process?

Statistical Insights: Going Synthetic with Real-World Data

Real-world data has the potential to have a positive impact on the treatment of serious conditions, providing much-needed insights into the health and treatment of patients in an everyday setting…

Statistical Insights: The liberation of real-world data

The costs and complexities associated with drug development are fuelling the drive for more efficient healthcare delivery…

Statistical Insights: Belfast is where Exploristics’ heart is

Why Belfast is a great place to set up a life science business.

Statistical Insights: Why Getting Smaller Doesn’t Mean Thinking Smaller

In the wake of a tumultuous 2020, I have taken the opportunity to reflect on the progress Exploristics has made as a company and reappraise my reasons for setting it up.

Statistical Insights: Clinical trials after COVID-19

The challenges faced by the Pharmaceutical Industry have been well documented…

Statistical Insights: COVID-19

The COVID-19 pandemic has demonstrated the importance of science and the dedication of scientists in overcoming the challenges that we face…

Interviews

The Effective Statistician

Exploristics CEO, Aiden Flynn, joins Alexander Schacht on his Effective Statistician podcast to discuss the power of simulation in designing clinical studies.

Common Causes of Clinical Trial Failures

A discussion with Matthew Cardinal from Halloran Consulting Group.

People Always, Patients Sometimes

Exploristics’ CEO discusses how data simulation studies can reduce the risk and costs of clinical trials.

Webinars

KerusCloud Webinar July 2021: smarter clinical study design and analysis approaches using simulation

Most clinical trials fail, but simulations are revolutionising study design to improve success rates. Get ahead of the curve to learn more about this game changing approach!

Statistical Insights: Smarter Clinical Trial Design using Study Simulation Can Address Recruitment Challenges

With recruitment often a key barrier to study success, discover how smarter trial design using study simulation can help to relieve this

Statistical Insights: Drug Repurposing and Real-World Data: Lessons from COVID-19

How the pandemic has heightened interest in unlocking the value of RWD.

Statistical Insights: Designing clinical studies for success and not failure

Why aren’t biostatisticians involved earlier in the clinical trial design process?

Statistical Insights: Going Synthetic with Real-World Data

Real-world data has the potential to have a positive impact on the treatment of serious conditions, providing much-needed insights into the health and treatment of patients in an everyday setting…

Statistical Insights: The liberation of real-world data

The costs and complexities associated with drug development are fuelling the drive for more efficient healthcare delivery…

Statistical Insights: Belfast is where Exploristics’ heart is

Why Belfast is a great place to set up a life science business.

Statistical Insights: Why Getting Smaller Doesn’t Mean Thinking Smaller
Statistical Insights: Why Getting Smaller Doesn’t Mean Thinking Smaller

In the wake of a tumultuous 2020, I have taken the opportunity to reflect on the progress Exploristics has made as a company and reappraise my reasons for setting it up.

Statistical Insights: Clinical trials after COVID-19
Statistical Insights: Clinical trials after COVID-19

The challenges faced by the Pharmaceutical Industry have been well documented…

exploristics-statistical-insights-COVID-19
Statistical Insights: COVID-19

The COVID-19 pandemic has demonstrated the importance of science and the dedication of scientists in overcoming the challenges that we face…

Interviews

The Effective Statistician

Exploristics CEO, Aiden Flynn, joins Alexander Schacht on his Effective Statistician podcast to discuss the power of simulation in designing clinical studies.

Common Causes of Clinical Trial Failures
Common Causes of Clinical Trial Failures

A discussion with Matthew Cardinal from Halloran Consulting Group.

exploristics spencer health solutions
People Always, Patients Sometimes

Exploristics’ CEO discusses how data simulation studies can reduce the risk and costs of clinical trials.

Webinars

KerusCloud Webinar July 2021: smarter clinical study design and analysis approaches using simulation

Most clinical trials fail, but simulations are revolutionising study design to improve success rates. Get ahead of the curve to learn more about this game changing approach!

White Papers

White Papers

Better Adherence, Higher Engagement
Better Adherence, Higher Engagement:
Finding The Clinical Trials Sweet Spot

Clinical trial sponsors and clinical research organizations must work through an ever-expanding set of challenges to ensure their studies of new drugs produce valid results. And they must do so while strictly managing costs and timelines. As more trials make use of inhome settings, digital technologies and realtime patient data, the pressure increases to efficiently manage a process that’s dramatically different from the traditional methods of direct observation inside the walls of a clinic.

exploristics scendea engaging with regulation on novel statistical approaches to clinical development
Engaging With Regulators On Novel Statistical Approaches To Clinical Development

The Pharmaceutical Industry is undergoing significant change as it faces extreme pressure to deliver new treatments to market at a time of increased spending in R&D. Multiple economic pressures are being exerted on the industry, ranging from an impending patent cliff, a decrease in income due to greater competition from generics and biosimilars, to demands on drug pricing by governments.

Want to find out more? Get in touch.

    Click here to join our mailing list for occasional company updates.